Recent Articles from GlobeNewswire

TORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Altus Group Limited (“Altus Group”) (TSX: AIF), a leading provider of commercial real estate (“CRE”) intelligence, today announced that it has taken up and paid for 2,855,696 of its common shares (“Shares”) at a price of C$57.00 per Share (the “Purchase Price”) under Altus Group’s substantial issuer bid (the “SIB”) to repurchase for cancellation a number of its Shares for an aggregate purchase price not to exceed C$350 million.

SUNNYVALE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- eGain Corporation (NASDAQ: EGAN), the leading AI knowledge platform for customer service, today announced that SELCO Community Credit Union has selected the eGain AI Knowledge Hub and AI Agent software to modernize its enterprise knowledge management and empower employees across the organization.

CHICAGO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Amplify ETFs today announced that the net asset value (NAV) of the Amplify BlackSwan Growth & Treasury Core ETF (SWAN) was decreased by $1.2713 per share on Friday, Jan. 9, 2026. This adjustment is a result of a security pricing error in calculating the Fund’s NAV.

RESTON, VA, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Stride Inc. (NYSE: LRN) announced today it plans to discuss its second quarter fiscal year 2026 financial results during a conference call scheduled for Tuesday, January 27, 2026 at 5:00 p.m. eastern time (ET). 

BROOKFIELD, News, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Brookfield Renewable (NYSE: BEP, BEPC; TSX: BEP.UN, BEPC) (“Brookfield Renewable”) today announced that it has agreed to issue C$500 million aggregate principal amount of Series 20 Notes (the “Notes”), due January 15, 2056, which will bear interest at a rate of 5.204% per annum.

QUÉBEC CITY, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Robex Resources Inc. (“Robex” or the “Company”) is pleased to announce it has obtained a final order from the Québec Superior Court (Commercial Division) approving the previously announced merger with Predictive Discovery Limited (“Predictive”) pursuant to which Predictive, through its direct wholly-owned subsidiary, will acquire all of the issued and outstanding common shares of Robex (“Robex Shares”) by way of a statutory plan of arrangement under the Business Corporations Act (Québec) (“Arrangement”).

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

ST. LOUIS, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BellRing Brands, Inc. (NYSE:BRBR) today announced it will release its financial results for the first quarter of fiscal year 2026 and its fiscal year 2026 outlook on February 3, 2026 at 7:00 a.m. ET. The release will be followed by a conference call at 8:30 a.m. ET to discuss the results and outlook. Darcy H. Davenport, President and Chief Executive Officer, and Paul A. Rode, Chief Financial Officer, will participate in the call.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

RONAN, Mont., Jan. 13, 2026 (GLOBE NEWSWIRE) -- AirJoule Technologies Corporation (NASDAQ: AIRJ) (“AIRJ” or the “Company”) today announced the commencement of an underwritten public offering of shares of its Class A common stock, par value $0.0001 per share (“Class A common stock”), pursuant to an effective shelf registration statement on Form S-3 (File No. 333-291527) (the “Registration Statement”) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Air Products and Chemicals, Inc. (“Air Products” or the “Company”) (NYSE: APD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SNDL Inc. (“SNDL” or the “Company”) (NASDAQ: SNDL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Above Foods Ingredients Inc. (“Above Food” or the “Company”) (NASDAQ: ABVE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Graphic Packaging Holding Company (“Graphic Packaging” or the “Company”) (NYSE: GPK).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  LENZ Therapeutics, Inc. (“LENZ” or the “Company”) (NASDAQ: LENZ).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Lakeland Industries, Inc. (“Lakeland” or the “Company”) (NASDAQ: LAKE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The new daily REVIVE series “JAY WALKER” airs at 7:00 PM ET and delivers conversation + tools in a purpose-driven format

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation (“Xoma” or the “Company”) (NASDAQ: XOMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ramaco Resources, Inc. (“Ramaco” or the “Company”) (NASDAQ: METC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rezolute, Inc. (“Rezolute” or the “Company”) (NASDAQ: RZLT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aerovironment, Inc. (“Aerovironment” or the “Company”) (NASDAQ: AVAV). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Chicago, January 13, 2026, Jan. 13, 2026 (GLOBE NEWSWIRE) -- North Park University (NPU) has received an $8,184,203 grant from Lilly Endowment Inc. for its seminary, North Park Theological Seminary, to launch One Covenant Community, a collaborative project that aims to cultivate pastoral leadership across the Evangelical Covenant Church (ECC) by strengthening vocational discernment, theological education, credentialing, and lifelong support.  

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ETHZilla Corporation (“ETHZilla” or the “Company”) (NASDAQ: ETHZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

A search to name a successor is currently underway

BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned neurologist and epilepsy authority Dr. Orrin Devinsky, M.D., as Head of Clinical Strategy, a newly created leadership role.

MCLEAN, Va., Jan. 13, 2026 (GLOBE NEWSWIRE) -- HII (NYSE: HII) announced its Mission Technologies division was awarded a contract for the Missile Defense Agency Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) indefinite-delivery/indefinite-quantity (IDIQ) contract with a ceiling of $151 billion.

Conference Call Scheduled for 8:00 a.m. ET on February 12th, 2026

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) --

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. (“Galectin” or the “Company”) (NASDAQ: GALT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

DETROIT, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Alpine IQ (AIQ), the leading data and marketing platform for cannabis retailers and brands, today announced a major evolution of its Loops media product: direct-to-menu destination URLs that route every brand impression to the appropriate retailer’s menu, brand page, or product page.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Duluth Holdings Inc. (“Duluth” or the “Company”) (NASDAQ: DLTH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cogent Communications Holdings, Inc.  (“Cogent” or the “Company”) (NASDAQ: CCOI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

PERRYSBURG, Ohio, Jan. 13, 2026 (GLOBE NEWSWIRE) -- O-I Glass, Inc. (NYSE: OI) has scheduled its full year and fourth quarter 2025 conference call and webcast for Wednesday, February 11, 2026, at 8 a.m. EST. The Company’s news release for the full year and fourth quarter 2025 earnings will be issued after the market closes on Tuesday, February 10.

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

WILMINGTON, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of UniFirst Corporation (NYSE:UNF) today declared regular quarterly cash dividends of $0.365 per share (36.5 cents) on the Company's Common Stock and $0.292 per share (29.2 cents) on the Company's Class B Common Stock. Both dividends are payable on March 27, 2026 to shareholders of record on March 6, 2026.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of New Era Energy & Digital, Inc. (“New Era” or the “Company”) (NASDAQ: NUAI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Bgin Blockchain Limited (“Bgin” or the “Company”) (NASDAQ: BGIN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nutanix, Inc. (“Nutanix” or the “Company”) (NASDAQ: NTNX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. (“Organogenesis” or the “Company”) (NASDAQ: ORGO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the closing of its $50 million registered direct financing at a 30% premium. The registered direct offering included the sale of 2,030,314 shares of common stock at $6.71 per share (issue price). Certain investors received pre-funded warrants to purchase up to 5,421,250 shares at $6.7099 each, which reflects the share price minus a nominal exercise cost of $0.0001 per share. The offering also included series warrants to buy up to 3,725,782 shares at $13.42 per share (2x issue price) and another 3,725,782 shares at $20.13 per share (3x issue price). The $6.71 purchase price represented a 30% premium over the Nasdaq Global Market price on January 9, 2026. All shares in the offering were sold by Foghorn. The gross proceeds from the offering were approximately $50 million (excluding any proceeds to be received upon exercise of the series warrants).

WALTHAM, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Crane NXT, Co. (NYSE: CXT), a premier industrial technology company, today announced its schedule for the company’s fourth quarter and full year 2025 results.

CHICAGO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Mondelēz International, Inc. (Nasdaq: MDLZ) will release its fourth quarter 2025 financial results on Tuesday, February 03, 2026, at 4:05 p.m. ET and will host a conference call at 5:00 p.m. ET that day.Investors and analysts may participate via phone by calling 800-245-3047 from the United States and 203-518-9765 from other locations. To ensure timely access, participants should dial in approximately 10 minutes before the call starts. A listen-only webcast will be provided at www.mondelezinternational.com.A replay of the conference call will be available until February 10, 2026, by calling 800-839-9302 from the United States and 402-220-6082 from other locations. The access code for both the conference call and its rebroadcast is MDLZQ425. An archive of the webcast will be available on the company's website.About Mondelēz InternationalMondelēz International, Inc. (Nasdaq: MDLZ) empowers people to snack right in over 150 countries around the world. With 2024 net revenues of approximately $36.4 billion, MDLZ is leading the future of snacking with iconic global and local brands such as Oreo, Ritz, LU, Clif Bar and Tate's Bake Shop biscuits and baked snacks, as well as Cadbury Dairy Milk, Milka and Toblerone chocolate. Mondelēz International is a proud member of the Dow Jones Best-in-Class North America and World Indices, formerly Dow Jones Sustainability Indices. Visit www.mondelezinternational.com or follow the company on X at x.com/MDLZ.

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on January 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of an individual hired by BBOT in December 2025.

Consolidates 13 additional locations to continue modernizing the business, better utilize inventory and teams, and strengthen performance at remaining locations.

CHANTILLY, Va., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) will release fourth quarter and fiscal year 2025 financial results before the markets open on Wednesday, February 11, 2026. The company will also provide details related to 2026 guidance as part of the call.

Completed Seven Investments in New and Existing Portfolio Companies Representing $42.9 Million in Funded Investments

EVP Matt Delly to Lead Purchasing and Merchandising Functions

WESTCHESTER, Ill., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions to the food manufacturing industry, will release its fourth quarter and full year 2025 financial results for the period ended December 31, 2025, before the market opens Tuesday, February 3, 2026.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) --

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

New York, NY, Jan. 13, 2026 (GLOBE NEWSWIRE) -- byNordic Acquisition Corporation (“BYNO” or the “Company”), a special purpose acquisition company, announced today that the Company has timely deposited into the Company’s trust account (the “Trust Account”), an aggregate of $17,470, in order to extend the period of time the Company has to complete a business combination for an additional one (1) month period, from January 12, 2026 to February 12, 2026 (the “Extension”). The Extension is the sixth of up to twelve (12) one-month extensions permitted under the August 8, 2025 amendment to the Company’s Amended and Restated Certificate of Incorporation that allows the Company’s board of directors, in its sole discretion and without another stockholder vote, to elect to extend the termination date by one additional month each time up until August 12, 2026, or the closing of the Company’s initial business combination.

Exclusive U.S. Distribution Partnership with Enlight Medical Ltd. Enables Kaneka Medical America LLC to Bring Novel Neurovascular Guidewire Technology to the U.S. Market

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Klarna Group PLC (“Klarna” or the “Company”) (NYSE: KLAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Apogee Enterprises, Inc. (“Apogee” or the “Company”) (NASDAQ: APOG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AST SpaceMobile, Inc. (“AST” or the “Company”) (NASDAQ: ASTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of First Solar, Inc. (“First Solar” or the “Company”) (NASDAQ: FSLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated (“Teleflex” or the “Company”) (NYSE: TFX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BigBear.ai Holdings, Inc. (“BigBear” or the “Company”) (NYSE: BBAI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. (“Quantum” or the “Company”) (NASDAQ: QNTM).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sigma Lithium Corporation (“Sigma Lithium” or the “Company”) (NASDAQ: SGML).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Smartsheet Inc. (“Smartsheet” or the “Company”) (NYSE: SMAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE: ARDT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sprouts Farmers Market, Inc. (“Sprouts” or the “Company”) (NASDAQ: SFM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Charming Medical Ltd. (“Charming” or the “Company”) (NASDAQ: MCTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.